百普赛斯 reported revenue of ¥0.50B for the period ended 2026-06-30, +29.0% year on year. Net income was ¥0.10B, a 19.7% net margin on a 90.3% gross margin. The largest revenue line is 重组蛋白 at 80% of the total. Free cash flow for the period was ¥0.01B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.50B | +29.0% |
| Gross profit | ¥0.45B | — |
| Operating income | ¥0.10B | — |
| Net income | ¥0.10B | +17.9% |
| Gross margin | 90.3% | Net margin 19.7% |
| Revenue Q/Q | +12.1% | — |
| Segment | Revenue | Share |
|---|---|---|
| 重组蛋白 | ¥0.40B | 80.4% |
| 抗体及其他试剂 | ¥0.08B | 15.1% |
| 技术服务 | ¥0.01B | 2.8% |
| 其他(补充) | ¥0.01B | 1.7% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.05B | 9.7% |
| R&D | ¥0.10B | 19.1% |
| SG&A | ¥0.22B | 43.6% |
| Tax & other | ¥0.01B | 1.3% |
| Item | Amount |
|---|---|
| Total assets | ¥3.01B |
| Total liabilities | ¥0.35B |
| Shareholders' equity | ¥2.66B |
| Equity / assets | 88.4% |
| Operating cash flow | ¥0.06B |
| Capital expenditure | ¥0.05B |
| Free cash flow | ¥0.01B |
| Cash conversion (OCF / net income) | 98% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
严牌股份 ・ 久盛电气 ・ 百胜智能 ・ 亚康股份 ・ 鸿富瀚 ・ 可孚医疗 ・ 戎美股份 ・ 拓新药业 ・ 华润材料 ・ 深城交 ・ 争光股份 ・ 华兰股份
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies